創建集團控股(01609.HK):上市複核委員會決定維持上市委員會的決定
格隆匯5月13日丨創建集團控股(01609.HK)發佈公吿,2022年5月12日,公司接獲聯交所函件,通知公司,經考慮公司及上市科提交的所有資料(書面及口頭)後,上市復核委員會決定維持上市委員會的決定,並根據上市規則第6.01(4)條將股份停牌。
上市複核委員會認為,此為已構成反向收購的連串交易(包括先前收購事項及出售事項),其中出售事項為該連串交易的最後一步(應用上市規則第14.06B條所載原則)。公司不同意上市複核委員會的決定,並將提出申請以取得複核許可,以於香港高等法院原訟法庭就上市複核委員會的決定進行司法複核。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.